SUBSCRIBE
SUBSCRIBE

Phase II

Drug Development
Researchers Continue to Face Several Hurdles in COVID-19 Clinical Trials
Despite the urgent need for more research into the coronavirus, the New York Times reported on August 14 that there have been numerous testing delays, staffing shortages and space constraints tying up the process.
August 18, 2020
 · 
2 min read
 · 
Krystle Vermes
Policy
Biopharma Update on the Novel Coronavirus: August 19
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 19, 2020.
August 17, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Izencitinib didn't meet the primary endpoints in i
Drug Development
Unity Bio’s Pain Drug Flunks Phase II Arthritis Trial
UNITY Biotechnology reported that the 12-week results from its Phase II study of UBX0101 in moderate-to-severe painful osteoarthritis (OA) of the knee failed to show improvement over placebo.
August 17, 2020
 · 
3 min read
 · 
Mark Terry
Policy
Biopharma Update on the Novel Coronavirus: August 17
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 17, 2020.
August 17, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
Drug Development
Sinopharm Publishes Positive Data from Phase I/II COVID-19 Vaccine Study
A COVID-19 vaccine candidate developed by Chinese pharmaceutical company Sinopharm triggered antibody-based immune responses in early and mid-stage trials.
August 14, 2020
 · 
2 min read
 · 
Alex Keown
Drug Development
Biopharma Update on the Novel Coronavirus: August 14
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 14, 2020.
August 13, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Drug Development
Study Highlights Continued Concern Over Lack of Racial Diversity in COVID-19 Studies
A recent report in the New England Journal of Medicine reveals that the racial and ethnic minority groups most negatively-impacted by COVID-19 are also the least represented in these clinical studies.
August 12, 2020
 · 
2 min read
 · 
Alex Keown
Policy
Biopharma Update on the Novel Coronavirus: August 12
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.
August 11, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Update on the Novel Coronavirus: August 10
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.
August 10, 2020
 · 
2 min read
 · 
BioSpace Editorial Staff
BioCapital
Clinical Catch-Up: August 3-7
It was a moderately busy week for clinical trial news, with some particularly interesting announcements related COVID-19 vaccine trials. Here’s a look.
August 6, 2020
 · 
8 min read
 · 
Mark Terry
Load More
PRESS RELEASES
Drug Development
Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome
September 18, 2023
 · 
6 min read
Drug Development
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
September 18, 2023
 · 
5 min read
Drug Development
AlzeCure Gets an Abstract on Phase II Clinical Data with ACD440 for Neuropathic Pain Accepted at Pain Conference
September 18, 2023
 · 
5 min read
Drug Development
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH
September 15, 2023
 · 
6 min read
Drug Development
Harpoon Therapeutics Announces First Patients with Small Cell Lung Cancer Dosed in HPN328 Combination Cohort
September 15, 2023
 · 
4 min read
Drug Development
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL)
September 14, 2023
 · 
4 min read
Drug Development
Positive results from the Phase II study of uTRACE in brain cancer presented at the World Molecular Imaging Congress (WMIC) 2023 in Prague
September 14, 2023
 · 
3 min read
Drug Development
Anavex’s Phase 2b/3 Trial of Blarcamesine (ANAVEX®2-73) in Patients with Alzheimer’s Disease Shows Robust Clinical Efficacy and Slows NeurodegenerationSignificant Reduction of Amyloid Beta Biomarkers of Alzheimer’s Pathology
September 14, 2023
 · 
6 min read
Drug Development
Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
September 13, 2023
 · 
10 min read
Drug Development
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
September 13, 2023
 · 
7 min read
Business
Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart (formerly ADX-914) for Severe Alopecia Areata
September 13, 2023
 · 
7 min read
Drug Development
Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer
September 13, 2023
 · 
4 min read
Drug Development
Alzheon Reports Industry-Leading Biomarker, Brain Preservation and Clinical Benefits Following 24 Months of Treatment in Phase 2 Trial of Oral ALZ-801 (Valiltramiprosate) in Patients with Early Alzheimer’s Disease
September 13, 2023
 · 
14 min read
Drug Development
J INTS BIO, WCLC 2023 - Presentation of Phase 1/2 study of ‘JIN-A02', a Novel Oral 4th Generation EGFR TKI
September 13, 2023
 · 
1 min read
Drug Development
Caliway Announces CBL-514 Phase 2 Study Topline Results for Dercum’s Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of Over 50% and Reduced Pain by 4.7
September 13, 2023
 · 
6 min read
Drug Development
Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023
September 12, 2023
 · 
3 min read
Drug Development
Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease
September 12, 2023
 · 
9 min read
Drug Development
Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH80 for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder
September 12, 2023
 · 
10 min read
Drug Development
Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
September 12, 2023
 · 
3 min read
Drug Development
A Phase 2 Study of Anti-Siglec-15 Antibody, NC318, in Combination with Pembrolizumab (NCT04699123) Demonstrates Clinical Activity in Patients with Advanced PD-1 Axis Inhibitor Refractory NSCLC
September 12, 2023
 · 
5 min read
Load More